NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
NewcelX Ltd., a clinical-stage regenerative medicine company, announced that it obtained a patent in Brazil protecting the manufacturing process of its lead compound NCEL-101 until 2036. The company recently had a successful FDA Pre-IND meeting for NCEL-101 combined with Eledon's immunotherapy tegoprubart targeting type 1 diabetes. This positions N…